SOHO 2023 | IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares the findings of a sub-group analysis of the Phase III IKEMA study (NCT03275285) which investigated isatuximab in combination with carfilzomib and dexamethasone (Isa‐Kd) in patients with relapsed/refractory multiple myeloma (R/R MM). In this analysis, the very good partial response (VGPR) rates, measurable residual disease (MRD) negativity and progression-free survival (PFS) with Isa-Kd versus Kd were compared in patients with 1q21 gain, with Isa-Kd resulting in favorable long-term outcomes. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: BMS, Janssen, Sanofi Consultant: Pfizer, GSK
